50 likes | 133 Views
Moving Promising Technologies off the Shelf: Commentary from the Private Sector. Chris Wagner President & CEO Sirius Genomics . Background. 20+ years of commercialization in applied science Pharmaceutical & Biotechnology Diagnostics Medical devices Large companies & small companies
E N D
Moving Promising Technologies off the Shelf: Commentary from the Private Sector Chris Wagner President & CEO Sirius Genomics
Background • 20+ years of commercialization in applied science • Pharmaceutical & Biotechnology • Diagnostics • Medical devices • Large companies & small companies • Pre human to post commercial • Commercialized products in Canada, USA, Europe, Asia • Direct P&L responsibility for >$22 B in cumulative revenues • CEO Sirius Genomics • BOD and SAB for several research based organizations
My Practical Experience • Commercial orientation from day one is a must • If commercial is correct technical risk is the only risk • Commercial orientation = customer orientation • Companies usually commercialize products not universities or governments • Companies are either the Customer or a good proxy • Products from science are global not just Canadian • Commercial orientation is difficult for some researchers; often not willing to walk away from an idea
Is the Issue Properly Framed • Limited success of Canadian research translation • TCOS framework captures success components • Global nature of scientific commercialization should be more explicit • Customer centric thinking should be emphasized • Private sector involvement should be emphasized
Policy Options Moving Forward • Scientists who integrate TCOS will be more successful in moving products off the shelf • Enhance TCOS framework with: global focus, customer centric, company or end user involvement • Consider “entrepreneur in residence” model • Consider a link between continued funding and legitimate adoption of TCOS